Results from a 36-Week Open-Label Study of Recombinant Human Growth Hormone and Testosterone in Facioscapulohumeral Muscular Dystrophy (FSHD)

被引：0

作者：

Heatwole, Chad ^{[1
]}

Luebbe, Elizabeth ^{[1
]}

Hamel, Johanna ^{[1
]}

Mongiovi, Philip ^{[1
]}

Ciafaloni, Emma ^{[1
]}

Dilek, Nuran ^{[1
]}

Martens, William ^{[1
]}

Weber, David ^{[2
]}

Hani, Rashid ^{[1
]}

Allen, Jamie ^{[1
]}

Smith, Claire ^{[1
]}

Howell, Samantha ^{[1
]}

Rosero, Spencer ^{[1
]}

Eichinger, Katy ^{[1
]}

Baker, Linday ^{[1
]}

Dekdebrun, Jeanne ^{[1
]}

Hilbert, Jim ^{[1
]}

Varma, Anika ^{[1
]}

McDermott, Michael ^{[1
]}

Thornton, Charles ^{[1
]}

Moxley, Richard ^{[1
]}

机构：

[1] Univ Rochester Med Ctr, Rochester, NY USA

[2] Childrens Hosp Philadelphia, Philadelphia, PA USA

来源：

NEUROLOGY | 2023年 / 100卷 / 17期

关键词：

D O I：

10.1212/WNL.0000000000202958

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

S48.009

引用

页数：5

共 50 条

[21] Risperidone in the treatment of mixed state bipolar patients: Results from a 24-week, multicenter, open-label study in Korea
Woo, Young Sup
Bahk, Won-Myong
Jon, Duk-In
Chung, Sang-Keun
Lee, Sang-Yeol
Ahn, Yong Min
Pae, Chi-Un
Cho, Hyun-Sang
Kim, Jeong-Gee
Hwang, Tae-Yeon
Lee, Hong-Seok
Min, Kyung Joon
Lee, Kyung-Uk
Yoon, Bo-Hyun
PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2010, 64 (01) : 28 - 37
[22] Safety and tolerability of levomilnacipran SR in major depressive disorder: results from an open-label, 48-week extension study
Mago, R.
Forero, G.
Greenberg, W. M.
Gommoll, C.
Chen, C.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S330 - S330
[23] Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
Rajnish Mago
Giovanna Forero
William M. Greenberg
Carl Gommoll
Changzheng Chen
Clinical Drug Investigation, 2013, 33 : 761 - 771
[24] Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
Mago, Rajnish
Forero, Giovanna
Greenberg, William M.
Gommoll, Carl
Chen, Changzheng
CLINICAL DRUG INVESTIGATION, 2013, 33 (10) : 761 - 771
[25] Growth hormone deficiency and replacement therapy in Japan: Results of placebo-controlled double-blind study and open-label extension study
Shimatsu, A.
Tai, S.
Kato, Y.
Kohno, H.
Tanaka, T.
Teramoto, A.
Chihara, K.
DECADE OF HYPOCCS: THE CHANGING FACE OF PITUITARY DISEASE, 2008, 10 : 171 - +
[26] Senolytics in Idiopathic Pulmonary Fibrosis: Preliminary Results from a First-in-Human, Open-Label, Pilot Study
Nambiar, A. M.
Justice, J. N.
Pascual, R.
Hashmi, S. K.
Tchkonia, T.
LeBrasseur, N. K.
Kirkland, J. L.
Musi, N.
Kritchevsky, S. B.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
[27] Phase IV, open-label, randomized study of low-dose recombinant human follicle-stimulating hormone protocols for ovulation induction
Gamal I Serour
Mohamed Aboulghar
Awatef Al Bahar
Jean-Noel Hugues
Khaled Esmat
Reproductive Biology and Endocrinology, 12
[28] Long-Term Efficacy of Adjunctive Cariprazine in Patients With MDD: Results From an Open-Label 26-Week Safety Study
Masand, Prakash
Vieta, Eduard
Waraich, Simranpreet
Kramer, Ken
Kerolous, Majid
NEUROPSYCHOPHARMACOLOGY, 2023, 48 : 263 - 264
[29] Phase IV, open-label, randomized study of low-dose recombinant human follicle-stimulating hormone protocols for ovulation induction
Serour, Gamal I.
Aboulghar, Mohamed
Al Bahar, Awatef
Hugues, Jean-Noel
Esmat, Khaled
REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, 2014, 12
[30] Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study
Yamasaki, K.
Nakagawa, H.
Kubo, Y.
Ootaki, K.
BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (03) : 741 - 751

← 1 2 3 4 5 →